October 25, 2022 – Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Agnieszka Blum, MD, PhD has joined the company’s Board of Management. She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development.
Agnieszka Blum, MD, PhD will continue her mission as the General Director of the Immunology Business Unit at Ardigen, where she focuses on developing AI platforms to solve therapy development problems in cell therapies, cancer vaccines, and TCR-mimicking antibodies.
Agnieszka Blum, MD, PhD has served as the General Director of Immunology since October 2020. She is board-certified medical doctor in Hematology/ Oncology as well as Internal Medicine, with more than 10 years of experience in patient care. During her time at the Charité Universitätsmedizin Berlin in Germany, Blum, MD, PhD played a central role in developing a GMP-compliant clinical platform for the use of TCR based cellular therapy in refractory AML, high-risk multiple myeloma and metastatic melanoma. In the context of complex government-sponsored initiatives she was able to coordinate activities of multidisciplinary teams including research, manufacturing, clinical and pathology. While serving as Consultant Hematologist and NGS Laboratory Manager at Mater Misericordiae University Hospital in Dublin in Ireland, Blum, MD, PhD successfully implemented next-generation sequencing diagnostics across different disciplines.
“I feel very privileged to take on this role at such an exciting time where the emergence of big data and new technologies has revolutionized the process and strategies to tackle drug development. Ardigen’s mission of accelerating the drug discovery process fulfills my physician’s dream of making precision medicine more available” – comments Agnieszka Blum, MD, PhD.
“By joining the Ardigen Management Board, Blum, MD, PhD will bring broad knowledge and clinical expertise in the field of Immuno-Oncology and modern therapy development. We are honored to receive her advice and guidance on the matters at the very core of key challenges of the data/AI-driven drug discovery approach” – said Janusz Homa, Ardigen CEO.
Ardigen is harnessing advanced AI methods for novel precision medicine. The company accelerates therapy development by designing immunity, decoding microbiomes, analysing biomedical images and providing digital drug discovery services. Ardigen’s team is rooted in biology and has extensive expertise in bioinformatics, machine learning and software engineering. The company’s in-house datasets, together with advanced AI platforms, empower the development of effective precision therapies.
More information at ardigen.com